Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

e effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

78
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Brooklyn, NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of ... with their quirky humor and excellent customer service. Images such as the Fonz in ... website to add some flavor to the humdrum spectroscopy field. , FireflySci is ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... N.C. , Aug. 27, 2015 ... decision by FedEx, UPS and The US Postal ... biological specimens classified as ,select agents, by the ... history of handling these sensitive shipments. ... global transportation regulations, trained and certified personnel to ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... the second time this year, a tech-based company in Wisconsin ... the public. Called an initial public offering, this kind of ... investors who are directly involved, but to others who may ... biotechnology company, has filed papers with the Securities and ...
... as are demands for the CIO's attention: electronic health ... and the like, combined with the standard fare of ... , ,The C-suite also is going through a major ... is that ability to execute corporate strategy, rather than ...
... Wis. - With the goal of transforming more ... Wisconsin-Madison has approved a new research entity - ... institute is a collaboration of the four UW-Madison health ... Veterinary Medicine. It will partner with the Marshfield Clinic ...
Cached Biology Technology:Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3Fire your CIO? If he's not implementing strategy, show him the door 2Fire your CIO? If he's not implementing strategy, show him the door 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... tells us that "no man is an island entire ... fact a walking, talking colony of microscopic creatures. Every ... bacterial fellow travelers. Since the early 20th century, scientists ... or inhibiting the formation of new species. A team ...
... As the use of biotechnology increases and more ... Agency,s approval to begin full-scale commercialization of seed ... pest monitoring will become even more difficult. ... risky because of larval behavior and greater adoption ...
... has been shown to detect marine pollutants such as oil ... biosensor, published in Environmental Toxicology and Chemistry , reveal ... tracking of oil spills. The biosensor has been developed ... and was tested in the Elizabeth River and Yorktown Creek ...
Cached Biology News:Could bacterial hitchhikers influence formation of new host species? 2Seed mixtures and insurance pest management: Future norm in the Corn Belt? 2New biosensor modelled on the immune system can detect, track and guide the clean-up of oil spills 2
... Rabbit polyclonal to JAK2 (phospho ... tested applications). Antigen: ... JAK2 around the phosphorylation site of ... Entrez Gene ID: ...
Harmful, Irritant, Combustible ,DEPC...
Permeabilization Solution, 5X...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: